The majority of molecular imaging studies investigating striatal DAT availability failed to find any significant differences between healthy controls and untreated patients with schizophrenia (15), and this finding was supported by the results of recent meta-analyses that included PET and SPECT studies (26, 37). This evidence concerns the gene SLC6A3 and schizophrenia.